Top

Published in:

01-06-2014 | Original Article

Discrete Improvement in Racial Disparity in Survival among Patients with Stage IV Colorectal Cancer: a 21-Year Population-Based Analysis

Authors: A. W. Castleberry, U. Güller, I. Tarantino, M. F. Berry, L. Brügger, R. Warschkow, T. Cerny, C. R. Mantyh, D. Candinas, M. Worni

Published in: Journal of Gastrointestinal Surgery | Issue 6/2014

Abstract

Purpose

Recently, multiple clinical trials have demonstrated improved outcomes in patients with metastatic colorectal cancer. This study investigated if the improved survival is race dependent.

Patients and Methods

Overall and cancer-specific survival of 77,490 White and Black patients with metastatic colorectal cancer from the 1988–2008 Surveillance Epidemiology and End Results registry were compared using unadjusted and multivariable adjusted Cox proportional hazard regression as well as competing risk analyses.

Results

Median age was 69 years, 47.4 % were female and 86.0 % White. Median survival was 11 months overall, with an overall increase from 8 to 14 months between 1988 and 2008. Overall survival increased from 8 to 14 months for White, and from 6 to 13 months for Black patients. After multivariable adjustment, the following parameters were associated with better survival: White, female, younger, better educated and married patients, patients with higher income and living in urban areas, patients with rectosigmoid junction and rectal cancer, undergoing cancer-directed surgery, having well/moderately differentiated, and N0 tumors (p < 0.05 for all covariates). Discrepancies in overall survival based on race did not change significantly over time; however, there was a significant decrease of cancer-specific survival discrepancies over time between White and Black patients with a hazard ratio of 0.995 (95 % confidence interval 0.991–1.000) per year (p = 0.03).

Conclusion

A clinically relevant overall survival increase was found from 1988 to 2008 in this population-based analysis for both White and Black patients with metastatic colorectal cancer. Although both White and Black patients benefitted from this improvement, a slight discrepancy between the two groups remained.

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians 2013;63:11-30.

Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T, Group EG-ITC, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft O, Australasian Gastro-Intestinal Trials G, Federation Francophone de Cancerologie D. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371:1007-1016.PubMedCentralPubMedCrossRef

Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England journal of medicine 2009;360:1408-1417.PubMedCrossRef

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England journal of medicine 2004;350:2335-2342.PubMedCrossRef

Golan T, Urban D, Berger R, Lawrence YR. Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location. Cancer 2013;119:3084-3091.PubMedCrossRef

Robbins AS, Siegel RL, Jemal A. Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol 2012;30:401-405.PubMedCrossRef

Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. The lancet oncology 2008;9:222-231.PubMedCrossRef

Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. Journal of the National Cancer Institute 2002;94:334-357.PubMedCrossRef

Obeidat NA, Pradel FG, Zuckerman IH, Trovato JA, Palumbo FB, DeLisle S, Mullins CD. Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer. The American journal of managed care 2010;16:515-522.PubMed

10.

White A, Liu CC, Xia R, Burau K, Cormier J, Chan W, Du XL. Racial disparities and treatment trends in a large cohort of elderly African Americans and Caucasians with colorectal cancer, 1991 to 2002. Cancer 2008;113:3400-3409.PubMedCrossRef

11.

Breslin TM, Morris AM, Gu N, Wong SL, Finlayson EV, Banerjee M, Birkmeyer JD. Hospital factors and racial disparities in mortality after surgery for breast and colon cancer. J Clin Oncol 2009;27:3945-3950.PubMedCentralPubMedCrossRef

12.

Berry J, Caplan L, Davis S, Minor P, Counts-Spriggs M, Glover R, Ogunlade V, Bumpers K, Kauh J, Brawley OW, Flowers C. A black-white comparison of the quality of stage-specific colon cancer treatment. Cancer 2010;116:713-722.PubMedCentralPubMedCrossRef

13.

Zhang W, Ayanian JZ, Zaslavsky AM. Patient characteristics and hospital quality for colorectal cancer surgery. International journal for quality in health care: journal of the International Society for Quality in Health Care / ISQua 2007;19:11-20.CrossRef

14.

The National Academies. Available at: http://www7.nationalacademies.org/ocga/laws/PL106_525.asp. Last accessed 8 Nov 2013.

15.

SEER. National Cancer Institute, Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/. Last accessed 8 Nov 2013.

16.

Weiser MR, Gonen M, Chou JF, Kattan MW, Schrag D. Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol 2011;29:4796-4802.PubMedCentralPubMedCrossRef

17.

Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999;94:496-509.CrossRef

18.

de Haas RJ, Wicherts DA, Andreani P, Pascal G, Saliba F, Ichai P, Adam R, Castaing D, Azoulay D. Impact of expanding criteria for resectability of colorectal metastases on short- and long-term outcomes after hepatic resection. Annals of surgery 2011;253:1069-1079.PubMedCrossRef

19.

Wicherts DA, Miller R, de Haas RJ, Bitsakou G, Vibert E, Veilhan LA, Azoulay D, Bismuth H, Castaing D, Adam R. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Annals of surgery 2008;248:994-1005.PubMedCrossRef

20.

Adam R. Developing strategies for liver metastases from colorectal cancer. Seminars in oncology 2007;34:S7-11.PubMedCrossRef

21.

Onaitis MW, Petersen RP, Haney JC, Saltz L, Park B, Flores R, Rizk N, Bains MS, Dycoco J, D'Amico TA, Harpole DH, Kemeny N, Rusch VW, Downey R. Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. The Annals of thoracic surgery 2009;87:1684-1688.PubMedCrossRef

22.

Lam VW, Laurence JM, Pang T, Johnston E, Hollands MJ, Pleass HC, Richardson AJ. A systematic review of a liver-first approach in patients with colorectal cancer and synchronous colorectal liver metastases. HPB: the official journal of the International Hepato Pancreato Biliary Association 2013;

23.

Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, Gansert J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010;28:4697-4705.PubMedCrossRef

24.

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, Group CS. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381:303-312.PubMedCrossRef

25.

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D, McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-3506.PubMedCrossRef

26.

Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, von Moos R, Vieitez JM, Bouche O, Borg C, Steffens CC, Alonso-Orduna V, Schlichting C, Reyes-Rivera I, Bendahmane B, Andre T, Kubicka S, Investigators MLS. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The lancet oncology 2013;14:29-37.PubMedCrossRef

27.

Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer 2003;97:1528-1540.PubMedCrossRef

28.

James TM, Greiner KA, Ellerbeck EF, Feng C, Ahluwalia JS. Disparities in colorectal cancer screening: a guideline-based analysis of adherence. Ethnicity & disease 2006;16:228-233.

29.

Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev 2006;15:389-394.PubMedCrossRef

30.

Musa D, Schulz R, Harris R, Silverman M, Thomas SB. Trust in the health care system and the use of preventive health services by older black and white adults. American journal of public health 2009;99:1293-1299.PubMedCentralPubMedCrossRef

31.

Kennedy BR, Mathis CC, Woods AK. African Americans and their distrust of the health care system: healthcare for diverse populations. Journal of cultural diversity 2007;14:56-60.PubMed

32.

Meyerhardt JA, Niedzwiecki D, Hollis D, Saltz LB, Hu FB, Mayer RJ, Nelson H, Whittom R, Hantel A, Thomas J, Fuchs CS. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA: the journal of the American Medical Association 2007;298:754-764.CrossRef

33.

Meyerhardt JA, Giovannucci EL, Holmes MD, Chan AT, Chan JA, Colditz GA, Fuchs CS. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 2006;24:3527-3534.PubMedCrossRef

34.

Campbell PT, Patel AV, Newton CC, Jacobs EJ, Gapstur SM. Associations of recreational physical activity and leisure time spent sitting with colorectal cancer survival. J Clin Oncol 2013;31:876-885.PubMedCrossRef

35.

Laiyemo AO, Doubeni C, Pinsky PF, Doria-Rose VP, Bresalier R, Lamerato LE, Crawford ED, Kvale P, Fouad M, Hickey T, Riley T, Weissfeld J, Schoen RE, Marcus PM, Prorok PC, Berg CD. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. Journal of the National Cancer Institute 2010;102:538-546.PubMedCentralPubMedCrossRef

36.

West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 2010;28:272-278.PubMedCrossRef

37.

Mohile SG, Hardt M, Tew W, Owusu C, Klepin H, Gross C, Gajra A, Lichtman SM, Feng T, Togawa K, Ramani R, Katheria V, Hansen K, Hurria A, Cancer, Aging Research G. Toxicity of bevacizumab in combination with chemotherapy in older patients. The oncologist 2013;18:408-414.

Title: Discrete Improvement in Racial Disparity in Survival among Patients with Stage IV Colorectal Cancer: a 21-Year Population-Based Analysis
Authors: A. W. Castleberry
U. Güller
I. Tarantino
M. F. Berry
L. Brügger
R. Warschkow
T. Cerny
C. R. Mantyh
D. Candinas
M. Worni
Publication date: 01-06-2014
Publisher: Springer US
Published in: Journal of Gastrointestinal Surgery / Issue 6/2014
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-014-2515-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Discrete Improvement in Racial Disparity in Survival among Patients with Stage IV Colorectal Cancer: a 21-Year Population-Based Analysis

Abstract

Purpose

Patients and Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2014

The Burden of Gastrointestinal Anastomotic Leaks: an Evaluation of Clinical and Economic Outcomes

Liver Resection in the Elderly: Significance of Comorbidities and Blood Loss

Minimally Invasive Technique Leads to Decreased Morbidity and Mortality in Small Bowel Resections Compared to an Open Technique: An ACS-NSQIP Identified Target for Improvement

Systematic Review and Meta-analysis of Laparoscopic Versus Open Distal Gastrectomy

Peroral Endoscopic Myotomy (POEM): Feasible as Reoperation Following Heller Myotomy

Short- and Long-Term Results of Laparoscopic Versus Open Anti-Reflux Surgery: a Systematic Review and Meta-Analysis of Randomized Controlled Trials